The clinical trials sector was celebrated at the 2024 ACTA Trial of the Year Awards ceremony on International Clinical Trials Day.
ACTA is the peak body supporting and representing networks of clinician-researchers conducting investigator-initiated clinical trials, maintaining clinical quality registries, and operating clinical trial coordinating centres within the healthcare system.
ACTA Chair Professor Christopher Reid said the awards reinforce and celebrate innovative clinical trials' impact on healthcare delivery and patient care.
“Each year the nominations received are a testament to the extraordinary expertise, drive and imagination that exists in Australia for designing and conducting trials that change practice – both here and around the world,” said Professor Reid.
The 2024 ACTA award winners were the Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty (ASAP), BCG Vaccination to Reduce the impact of COVID-19 in hEalthcare workers (BRACE), The Melanoma Genomics Managing Your Risk Study, and The Recovery-focused Community support to Avoid readmissions and improve Participation after Stroke trial (ReCAPS).
The Trial of the Year Awards were established in 2016 to highlight the achievements that advance clinical practice and save or improve patients' lives every year. The awards are celebrated annually on International Clinical Trials Day.
